NCT04225026View on ClinicalTrials.gov

Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

December 28, 2021

Study Completion Date

March 27, 2022

Conditions
Esophagitis
Interventions
DRUG

GC4419 (avasopasem manganese)

90 mg, by 60-minute IV infusion, prior to each fraction of RT

Trial Locations (12)

29303

Spartanburg Regional Medical Center - Gibbs Cancer Center, Spartanburg

29601

St. Francis Hospital, Greenville

31904

IACT Health, Columbus

33606

Tampa General Hospital, Tampa

37920

University of Tennessee Medical Center, Knoxville

40202

University of Louisville, Louisville

44106

University Hospitals Cleveland Medical Center, Cleveland

52242

University of Iowa, Iowa City

64507

Cancer Care St. Joseph/Mosaic Life Care, Saint Joseph

85234

Banner MD Anderson Cancer Center, Gilbert

98201

Providence Regional Cancer Partnership, Everett

07753

Hackensack Meridian Health, Montclair

Sponsors
All Listed Sponsors
lead

Galera Therapeutics, Inc.

INDUSTRY

NCT04225026 - Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer | Biotech Hunter | Biotech Hunter